Aragen Life Sciences Files Rs 800 Cr IPO DRHP with SEBI
Aragen Life Sciences IPO filing with SEBI
Key Highlights
Aragen Life Sciences files DRHP for Rs 800 crore fresh IPO with SEBI. Funds to support debt repayment, capex, and general corporate purposes.
Aragen Life Sciences has filed its Draft Red Herring Prospectus (DRHP) with SEBI for an (IPO). The IPO includes a fresh issue worth Rs 800 crore and an offer for sale of up to 27,329,192 equity shares.
Proceeds from the fresh issue are earmarked for debt repayment and capital expenditure at its Hyderabad and Bengaluru facilities. These funds will also support general corporate purposes for Aragen Biologics, its subsidiary.
IPO Structure & Strategic Use
Established in 2000, Aragen operates as a fully integrated contract research, development, and manufacturing organization (CRDMO). It serves global innovator and emerging life sciences companies.
- : Rs 800 crore
- : Up to 27,329,192 equity shares
- Fresh Issue Use: Debt repayment, capital expenditure for new equipment, general corporate purposes
Market Position & Financial Performance
Aragen Life Sciences is the largest Indian CRDMO by breadth of solutions offered. It ranks among the top three in operating revenue among its Indian peers within a global CRDMO market valued at $171 billion in fiscal 2026.
In fiscal 2026, the company partnered with 591 customers globally. This included 16 of the top 20 Big Pharma companies as of March 31, 2026.
Key Financials for FY26
- from Operations: Rs 2,178.39 crore ( of 14.64%)
- Profit for the Year: Rs 257.64 crore (up 26.86%)
- Adjusted : Rs 593.77 crore (up 15.63%)
- Adjusted Profit for the Year: Rs 283.99 crore (up 29.91%)
- (ROCE): 18.18%
- (ROE): 11.96%
The IPO’s book running lead managers include Axis Capital, Citigroup Global Markets India, Goldman Sachs (India) Securities, and JM Financial.